Oncology- Our Service Offerings
Key Questions RAS Can Help You Answer
What is the current solid tumor clinical development landscape?
What are the key market impacting events?
What´s the strategy of major Oncology players?
What´s the positioning and strategy for a molecule of interest?
What are the upcoming innovation waves? What are the opportunities created by them?
What´s the current state-of-the-art in cancer biomarkers?
How to keep pace with the regulatory policies & payer positions across geographies?
What drug candidates/ companies are suitable for partnering or in-licensing for oncology therapeutics?
Featured Insights
Read Our Blogs
June 2, 2018
Abstract 4011: A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal junction cancer refractory to trastuzumab (Herceptin) combined with fluoropyrimidine and platinum: WJOG7112G. Conclusion: Continuation of trastuzumab beyond progression (TMB Strategy) in this patient population was not found to have the […]
June 2, 2018
Abstract 506: PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. Conclusion: Trastuzumab’s known side effects include a risk for heart problems. The women who had […]
September 11, 2017
Distribution of Anti Pd-1 / Anti PD-L1 by Phase Related Post Major Milestones In Cancer Research Top ASCO 2018 Abstracts To Watch Out For In Lymphoma Top ASCO 2018 Abstracts To Watch Out For In Gastrointestinal Cancers
July 17, 2017
As the regulatory frameworks for biosimilar development are evolving in both US and EU, more and more biosimilar developers are entering the competitive landscape. Many commercially successful Oncology biologics are going off-patent in next few years, presenting a lucrative opportunity for biosimilar development. The biosimilars pertaining to these biologics constitute […]
June 1, 2017
In ASCO 2017, it will be great to see the new treatment options i.e. IOs and their combinations paving their way in other tumors. It would be informative to see how the disease landscape has evolved with the advent of IOs in the last one year. Equally, it would be […]
May 31, 2017
An aggressive malignancy, Glioblastoma is an indication with one of the highest level of unmet need in oncology. Currently, Avastin and Temozolomide dominates the market. With GBM market estimated to reach $3.3B (G7 market) by 2024 (Globaldata), companies are trying out novel approaches. GBM pipeline is characterized by active early […]